More great news for Clinuvel, and yes why indeed not price sensitive? A quick search below comes up with 4 concrete examples of Orphan Drug Designation being granted and EACH ONE IS MARKET SENSITIVE as marked by the ASX. I could go on because there are plenty more but why the inconsistency. So what does Orphan Drug status do, it usually means tax credits for trials, a market exclusive period and less or no fees throughout the drug approval process.
Mesoblast MSB 15/02/24, Neuren NEU 3/9/21, Noxopharm NOX 4/10/23, Argenica AGN 15/11/23 All market sensitive but not CUV 29/4/24?
In my opinion this is very likely to be added as a label extension for the already approved and safe drug. Clinuvel did mention payors will reimburse for this terrible disease and the following statements in todays release are quite positive:
"The Committee for Orphan Medicinal Products (COMP) recognised the chronically severe nature of skin
symptoms in VP, the high unmet need, lack of alternative therapies, and afamelanotide’s potential as a VP
treatment.
The EMA considered clinical evidence from the CUV040 study – an open-label six-month study of six adult VP
patients – to be a sufficient proof-of-concept to enable a positive opinion on the ODD application for
SCENESSE®. The Agency reviewed the study endpoints and results on disease severity, ability to expose to
light, and quality of life as a potential clinical benefit for VP patients."
All IMO DYOR
- Forums
- ASX - By Stock
- CUV
- Ann: SCENESSE European Orphan Drug Designation for VP
Ann: SCENESSE European Orphan Drug Designation for VP, page-10
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.87 |
Change
-0.090(0.64%) |
Mkt cap ! $694.3M |
Open | High | Low | Value | Volume |
$14.00 | $14.07 | $13.84 | $834.5K | 60.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1134 | $13.86 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.89 | 127 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1134 | 13.860 |
1 | 72 | 13.850 |
1 | 656 | 13.840 |
2 | 4446 | 13.830 |
1 | 50 | 13.810 |
Price($) | Vol. | No. |
---|---|---|
13.930 | 312 | 1 |
13.950 | 312 | 1 |
13.970 | 312 | 1 |
13.990 | 312 | 2 |
14.080 | 1000 | 1 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online